Amy Yang, MD
Clinical Genetics (M.D.) · Portland, ORNPI 1902012180
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,317 of the $4,455 with a category attached, or 74.5%. Biomarin Pharmaceutical Inc. accounts for 73.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,893 and has fallen 92.4% since, to $219 in 2023.
Across 13 payments — averaging $342.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$3K
- Sanofi$976
- Dexcom, Inc.$140
- Ultragenyx Pharmaceutical Inc.$82
Across 16 payments — averaging $1929.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$15K
- Sanofi US Services Inc.$9K
- Shire North American Group Inc$7K
What the payments were for
- Travel & lodging$73617%
- Food & beverage$4029%
- Education$3,31774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 2 | $3,257 |
| Sanofi | 7 | $976 |
| Dexcom, Inc. | 1 | $140 |
| Ultragenyx Pharmaceutical Inc. | 3 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brineura$3,257
- NO PRODUCT DISCUSSED$736
- DEXCOM G7 GSS (161)$140
How this compares
Too few clinical genetics (m.d.) providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RavictiGlycerol Phenylbutyrate | 13 | $2,577,540 |
| GalafoldMigalastat Hcl | 15 | $473,637 |
| CerdelgaEliglustat Tartrate | 12 | $378,879 |
| Carbamazepine | 13 | $1,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiCerdelga | $976 | $378,87912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Portland
- Cary HardingPortland$215K
- Andrea PetersenPortland$5K
- Nicoleta VoianPortland$1K
- Kimberly KrippsPortland$154
- Jacob ReissPortland$85
- Dana SimpsonPortland$53
- Osvaldo SchirripaBend$119
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.